Allan Gobbs

Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases. Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.

Our technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug’s function and guide therapeutic development. We are comprised of a talented, diversely-skilled team, working together towards the mission of helping bring new therapies to patients with epigenetically-driven diseases.

At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease. Co-founded in 2015 by licensing technology out of McMaster University and Bloom Burton & Co., Triumvira is working to achieve this vision by developing a proprietary T cell Antigen Coupler (TAC) technology, thought to be safer and more efficacious than current cancer treatments including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. We are an emergent US company with operations in the United States and Canada. We bring together talent from a wide range of disciplines including immunobiology, drug development, fundraising, commercialization and finance, with decades of experience across big pharma and small biotech, multiple industries and academia. We are passionate about science that pushes the limits, the patients that drive the heart of our work, and the wellness of our employees. We embrace flexibility. If you are looking for a career where you are encouraged to be innovative, challenge the status quo, and have some fun while doing it, Triumvira is the place for you. For more information about Triumvira career opportunities, please see our Careers web page at: https://triumvira.com/contact-us/careers/

Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.

Iridias breakthrough molecular identity technology combines cybersecurity, blockchain, molecular science, robotics, and AI to create an immutable foundation of truth in global commerce. Were not just securing supply chains, were establishing a new bedrock of trust that will reshape how humanity conducts trade, protects innovation, and builds economic relationships. Our technology ensures the authenticity of critical materials, assets and products that power the global economy, setting new standards for transparency and security across industries.

Virry VR: innovative VR nature therapy and mindfulness for mental health is a series of real-imagery interactive and non-interactive experiences that transport you to the cradle of humankind — the African savannah. We know that exposure to nature is one of the most effective non-medicinal methods to improve mental wellbeing. This can be difficult for vulnerable people, or those living in urban areas. With VR we can immerse ourselves in nature from the safety and comfort of our home, hospital, school or office. Our carefully designed VR experiences are proven to rapidly improve psychological health. We have tested our technology to measure its effectiveness on the psycho-emotional state of a range of participants and work closely with a number of leading psychologists to ensure we are providing the best possible VR solutions. Our Virry Health package is designed for enterprises, healthcare providers and schools to bring the incredible benefits of nature immersion to the workplace, home, hospital or school.

Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.

Pharmacogenetic analyses offer insights into specific DNA variations that might impact how your body interacts with certain drugs. As an illustration, our documents shed light on particular DNA changes that could determine the efficiency of enzymes responsible for drug metabolism. Additionally, some of our pharmacogenetic evaluations come with Medication Insights. These insights delve into how specific DNA variations might alter your bodys reaction to particular drugs. Possessing a certain DNA variation could mean that your body metabolizes some drugs quicker or slower than the average person. However, the presence of such a variation doesnt necessarily affect the majority of drugs. A myriad of factors, both genetic and external, play a role in how effectively your body handles medications. Factors such as age, body mass, the health of your liver and kidneys, concurrent drug intake, and even lifestyle choices can influence this. Moreover, there might be other DNA changes, not covered in these analyses, that could influence drug metabolism. Its crucial to consult with a medical expert regarding how DNA variations might alter your drug metabolism. Its advised not to base medical decisions solely on these test outcomes. Before making any medical decisions, its recommended to get these results verified through a separate genetic analysis as prescribed by a healthcare professional. Advantages of PGxCare: ● AI-Powered Technology: PGxCare harnesses cutting-edge AI capabilities, enabling instantaneous analysis of pharmacogenetic data for the first time. This ensures rapid and accurate results tailored to individual needs. ● Extensive Drug Database: Our platform boasts the largest drug database across all clinical specialties, encompassing over 730 medications. This vast range ensures comprehensive analysis catering to diverse patient requirements.

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases. Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.

A network for entrepreneurs building in stealth. Submit your information here so investors can find you: harmonic.ai/get-discovered